{"id":454542,"date":"2021-03-10T07:03:20","date_gmt":"2021-03-10T12:03:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=454542"},"modified":"2021-03-10T07:03:20","modified_gmt":"2021-03-10T12:03:20","slug":"cybrexa-therapeutics-closes-25-million-series-b-financing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/","title":{"rendered":"Cybrexa Therapeutics Closes $25 Million Series B Financing"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>-Proceeds will advance the company\u2019s lead program into clinical trials-<\/em><br \/>\n        \n      <\/p>\n<p align=\"left\">NEW HAVEN, Conn., March  10, 2021  (GLOBE NEWSWIRE) &#8212; Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex\u2122 Peptide Drug Conjugate (PDC) tumor targeting platform, today announced the completion of its $25 million Series B financing. The financing included HighCape Capital and new investor Elm Street Ventures. Proceeds from the financing will be used to support the planned advancement of Cybrexa\u2019s lead candidate CBX-12 (alphalex\u2122-exatecan) into the clinic. The first patient dosing in the Phase 1 study is expected in the first half of 2021.<\/p>\n<p>\u201cWe are pleased that our efforts continue to be recognized and supported by our investors. This funding is a testament to our company&#8217;s progress, execution and the strength of our alphalex\u2122 platform technology,\u201d said Per Hellsund, President &amp; CEO of Cybrexa. \u201cThis round of financing will be deployed to support the planned Phase 1 study for CBX-12.\u201d<\/p>\n<p>CBX-12 is a novel treatment for solid tumors that includes a highly potent topoisomerase I inhibitor payload that is in the same class as the payloads used by antibody-drug conjugates (ADCs) ENHERTU<sup>\u00ae<\/sup> and TRODELVY\u2122.\u00a0In contrast to these ADCs, CBX-12 is able to target cancer cells independent of antigen overexpression, which should greatly expand the addressable patient populations. The positive results from the GLP toxicology study of CBX-12 will serve as a guide for the dosing regimen in the planned Phase I trial.<\/p>\n<p>\u201cWe believe Cybrexa\u2019s\u00a0technology and science form the basis for a robust development platform, capable of producing multiple targeted therapeutic options, for a variety of oncology indications,\u201d said Kevin Rakin, Partner of HighCape Capital. \u201cWe see the progress of CBX-12 into human trials as a significant milestone for the platform, as well as providing even more opportunities from a business perspective.\u201d<\/p>\n<p>\n        <strong>About CBX-12<\/strong>\n      <\/p>\n<p>CBX-12 is a novel treatment for solid tumors that includes a highly potent topoisomerase I inhibitor payload that is in the same class as the payloads used by antibody-drug conjugates (ADCs) ENHERTU<sup>\u00ae<\/sup> and TRODELVY\u2122.\u00a0In contrast to these ADCs, CBX-12 is able to target cancer cells independent of antigen overexpression, which should greatly expand the addressable patient populations. Positive results from the GLP toxicology study of CBX-12 will serve as a guide for dosing regimen for the planned Phase I trial of CBX-12, as Cybrexa filed the IND on February 19, 2021. CBX-12 is currently being investigated in collaboration with NCI in pre-clinical safety and efficacy studies in the solid tumor landscape. This partnership will also explore its therapeutic potential to conduct trials in a wide number of indications and in combination with other therapies such as immune-oncology and PARP inhibitors.<\/p>\n<p>\n        <strong>About the alphalex\u2122 Technology Platform <\/strong><br \/>\n        <br \/>The Cybrexa alphalex\u2122 technology platform \u2013 which consists of a pHLIP<sup>\u00ae<\/sup> peptide, linker, and small molecule anti-cancer agent (payload) \u2013 enables antigen-independent targeting of tumors and intracellular delivery of highly potent anticancer therapies, creating therapeutics that can revolutionize the standard of care.\u00a0pHLIP<sup>\u00ae<\/sup> peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces.\u00a0pHLIP<sup>\u00ae<\/sup> was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc.\u00a0alphalex\u2122 represents the disruptive next generation in tumor targeting.\u00a0View a video of the mechanism of action of the technology at www.cybrexa.com.<\/p>\n<p>\n        <strong>About Cybrexa <\/strong><br \/>\n        <br \/>Cybrexa is a privately-held biotechnology company dedicated to developing next-generation tumor-targeted cancer therapies using its alphalex\u2122 platform. The Company\u2019s lead candidate, CBX-12, an alphalex\u2122-exatecan conjugate, is expected to enter Phase I\/II in 2021 in advanced solid tumors. Cybrexa also has other preclinical toxin conjugate programs as well as synthetic lethality programs.\u00a0Cybrexa was founded by physician-scientists and has an experienced management team that has built numerous successful life sciences companies. For more information about Cybrexa, please visit www.cybrexa.com.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>Cybrexa Therapeutics<br \/>Lisa Rehm<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2QFbPmkqWY1i_9Kc2vP-zhroDSlqFSZS7sEzskuhYk6lna1rKp8axPqDeqcZmAYUnLSw1lVBLuT3hWlFS4rY3jPrpiAeTyjfA3eEKyhz-fE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">lisa.rehm@cybrexa.com<\/a><\/p>\n<p>Investor Relations<br \/>Stephanie Carrington<br \/>Tel: 646-277-1282<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZP0iZ3OgLmGDVzGIwW6VMcjK28exzbX8FJt8z5ozxygtdhwJ9kaMhyHV84iXXgtatTI29Kt3buVnWXDFLhlkmvEcl5o9FZUDqsMjYB5F6BLq616Cs5xd-y9nE5M_J8--RcuUdtlL-Rfjhl3BJDeOyg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Stephanie.Carrington@westwicke.com<\/a><\/p>\n<p>Media Relations<br \/>Mark Corbae<br \/>Tel: 203-682-8288<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a8D1JQwblHb5A355Dd1t_enUsegb-OWH1-i_oQSccXX5iesjTSYXQf-oZRkSVSlw13jafH1PP9CLIi7JGmktyC75-XO0lwvEgdb9BHPSFLU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Mark.Corbae@westwicke.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzYxNCM0MDU2MTI2IzIxODgwNDA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/1c6c28b5-5cb7-4e2b-a16a-91fa6d6bbf43\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>-Proceeds will advance the company\u2019s lead program into clinical trials- NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) &#8212; Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex\u2122 Peptide Drug Conjugate (PDC) tumor targeting platform, today announced the completion of its $25 million Series B financing. The financing included HighCape Capital and new investor Elm Street Ventures. Proceeds from the financing will be used to support the planned advancement of Cybrexa\u2019s lead candidate CBX-12 (alphalex\u2122-exatecan) into the clinic. The first patient dosing in the Phase 1 study is expected in the first half of 2021. \u201cWe are pleased that our efforts continue to be recognized and supported by our investors. This funding is a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cybrexa Therapeutics Closes $25 Million Series B Financing&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-454542","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cybrexa Therapeutics Closes $25 Million Series B Financing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cybrexa Therapeutics Closes $25 Million Series B Financing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"-Proceeds will advance the company\u2019s lead program into clinical trials- NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) &#8212; Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex\u2122 Peptide Drug Conjugate (PDC) tumor targeting platform, today announced the completion of its $25 million Series B financing. The financing included HighCape Capital and new investor Elm Street Ventures. Proceeds from the financing will be used to support the planned advancement of Cybrexa\u2019s lead candidate CBX-12 (alphalex\u2122-exatecan) into the clinic. The first patient dosing in the Phase 1 study is expected in the first half of 2021. \u201cWe are pleased that our efforts continue to be recognized and supported by our investors. This funding is a &hellip; Continue reading &quot;Cybrexa Therapeutics Closes $25 Million Series B Financing&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-10T12:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzYxNCM0MDU2MTI2IzIxODgwNDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybrexa-therapeutics-closes-25-million-series-b-financing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybrexa-therapeutics-closes-25-million-series-b-financing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cybrexa Therapeutics Closes $25 Million Series B Financing\",\"datePublished\":\"2021-03-10T12:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybrexa-therapeutics-closes-25-million-series-b-financing\\\/\"},\"wordCount\":662,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybrexa-therapeutics-closes-25-million-series-b-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NzYxNCM0MDU2MTI2IzIxODgwNDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybrexa-therapeutics-closes-25-million-series-b-financing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybrexa-therapeutics-closes-25-million-series-b-financing\\\/\",\"name\":\"Cybrexa Therapeutics Closes $25 Million Series B Financing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybrexa-therapeutics-closes-25-million-series-b-financing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybrexa-therapeutics-closes-25-million-series-b-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NzYxNCM0MDU2MTI2IzIxODgwNDA=\",\"datePublished\":\"2021-03-10T12:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybrexa-therapeutics-closes-25-million-series-b-financing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybrexa-therapeutics-closes-25-million-series-b-financing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybrexa-therapeutics-closes-25-million-series-b-financing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NzYxNCM0MDU2MTI2IzIxODgwNDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NzYxNCM0MDU2MTI2IzIxODgwNDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybrexa-therapeutics-closes-25-million-series-b-financing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cybrexa Therapeutics Closes $25 Million Series B Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cybrexa Therapeutics Closes $25 Million Series B Financing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/","og_locale":"en_US","og_type":"article","og_title":"Cybrexa Therapeutics Closes $25 Million Series B Financing - Market Newsdesk","og_description":"-Proceeds will advance the company\u2019s lead program into clinical trials- NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) &#8212; Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex\u2122 Peptide Drug Conjugate (PDC) tumor targeting platform, today announced the completion of its $25 million Series B financing. The financing included HighCape Capital and new investor Elm Street Ventures. Proceeds from the financing will be used to support the planned advancement of Cybrexa\u2019s lead candidate CBX-12 (alphalex\u2122-exatecan) into the clinic. The first patient dosing in the Phase 1 study is expected in the first half of 2021. \u201cWe are pleased that our efforts continue to be recognized and supported by our investors. This funding is a &hellip; Continue reading \"Cybrexa Therapeutics Closes $25 Million Series B Financing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-10T12:03:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzYxNCM0MDU2MTI2IzIxODgwNDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cybrexa Therapeutics Closes $25 Million Series B Financing","datePublished":"2021-03-10T12:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/"},"wordCount":662,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzYxNCM0MDU2MTI2IzIxODgwNDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/","name":"Cybrexa Therapeutics Closes $25 Million Series B Financing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzYxNCM0MDU2MTI2IzIxODgwNDA=","datePublished":"2021-03-10T12:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzYxNCM0MDU2MTI2IzIxODgwNDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NzYxNCM0MDU2MTI2IzIxODgwNDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybrexa-therapeutics-closes-25-million-series-b-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cybrexa Therapeutics Closes $25 Million Series B Financing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=454542"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454542\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=454542"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=454542"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=454542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}